Microdose tirzepatide is usually not positioned as the fastest path to maximum weight loss
Other GLP-1 and dual-agonist agents, including tirzepatide, are also in wide use, though not every GLP-1 on the market carries an FDA weight loss indication
doi: 10.1245/s10434-010-1488-z 200 BenvengaSAntonelliA
Miranda-Daz AG, Pazarn-Villaseor L, Yanowsky-Escatell FG, Andrade-Sierra J
Prescribed by doctors
Most commercial insurance plans that cover GLP-1 for weight loss require prior authorization documenting: BMI at or above 30 (or 27 with a weight-related condition like hypertension, type 2 diabetes, dyslipidemia, or sleep apnea), and in some cases, documented prior attempts at lifestyle modification